Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model.

[1]  Rick W. Martin,et al.  A comparison of three tocolytics for preterm labor: a randomized clinical trial , 2014, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  H. Takano,et al.  Demonstration of the Clathrin- and Caveolin-Mediated Endocytosis at the Maternal–Fetal Barrier in Mouse Placenta after Intravenous Administration of Gold Nanoparticles , 2013, The Journal of veterinary medical science.

[3]  R. Bajoria,et al.  Effect of lipid composition of cationic SUV liposomes on materno-fetal transfer of warfarin across the perfused human term placenta. , 2013, Placenta.

[4]  C. Crowther,et al.  Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. , 2013, The Cochrane database of systematic reviews.

[5]  Sijin Liu,et al.  The capability of quantum dots in crossing the placental barrier and the potential influence on erythrocytes. , 2013, Journal of nanoscience and nanotechnology.

[6]  Hazem Ali,et al.  Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model. , 2013, International journal of pharmaceutics.

[7]  V. Demin,et al.  Transfer of Silver Nanoparticles through the Placenta and Breast Milk during in vivo Experiments on Rats , 2013, Acta naturae.

[8]  Antonio Pietroiusti,et al.  Biodistribution and toxicity of pegylated single wall carbon nanotubes in pregnant mice , 2013, Particle and Fibre Toxicology.

[9]  Bengt Fadeel,et al.  Interactions of engineered nanoparticles with organs protected by internal biological barriers. , 2013, Small.

[10]  E. Söderstjerna,et al.  Gold- and Silver Nanoparticles Affect the Growth Characteristics of Human Embryonic Neural Precursor Cells , 2013, PloS one.

[11]  Robert S Plumb,et al.  Global metabolic profiling of animal and human tissues via UPLC-MS , 2012, Nature Protocols.

[12]  P. Middleton,et al.  Oral betamimetics for maintenance therapy after threatened preterm labour. , 2012, The Cochrane database of systematic reviews.

[13]  M. Inagaki,et al.  Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model. , 2012, Life sciences.

[14]  Gynecologists.  ACOG practice bulletin no. 127: Management of preterm labor. , 2012, Obstetrics and gynecology.

[15]  P. Wick,et al.  Knocking at the door of the unborn child: engineered nanoparticles at the human placental barrier. , 2012, Swiss medical weekly.

[16]  Xin Wang,et al.  Development of a liquid chromatography-tandem mass spectrometry method for measuring plasma and uterine tissue levels of indomethacin in rabbits treated with indomethacin-medicated Cu-IUDs. , 2012, Contraception.

[17]  J. Zelikoff,et al.  Cadmium associated with inhaled cadmium oxide nanoparticles impacts fetal and neonatal development and growth. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  M. Ferrari,et al.  Size of the nanovectors determines the transplacental passage in pregnancy: study in rats. , 2011, American journal of obstetrics and gynecology.

[19]  J. Keelan,et al.  Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure. , 2011, Current pharmaceutical biotechnology.

[20]  Yasuo Yoshioka,et al.  Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. , 2011, Nature nanotechnology.

[21]  R. Kannan,et al.  Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[22]  R. Romero,et al.  Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. , 2010, International journal of pharmaceutics.

[23]  Qiang Wu,et al.  Transfer of quantum dots from pregnant mice to pups across the placental barrier. , 2010, Small.

[24]  Peter Wick,et al.  Barrier Capacity of Human Placenta for Nanosized Materials , 2009, Environmental health perspectives.

[25]  Mauro Ferrari,et al.  Nanomedicine--challenge and perspectives. , 2009, Angewandte Chemie.

[26]  P. Myllynen,et al.  Kinetics of gold nanoparticles in the human placenta. , 2008, Reproductive toxicology.

[27]  Mauro Ferrari,et al.  Design maps for nanoparticles targeting the diseased microvasculature. , 2008, Biomaterials.

[28]  Mauro Ferrari,et al.  Antibiological barrier nanovector technology for cancer applications , 2007, Expert opinion on drug delivery.

[29]  B. W. Barry,et al.  Enhancement in Drug Delivery , 2006 .

[30]  R. Davidson,et al.  A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. , 2006, The Journal of antimicrobial chemotherapy.

[31]  B. Godin,et al.  Vesicular Carriers for Enhanced delivery through the skin , 2006 .

[32]  B. Godin,et al.  Erythromycin ethosomal systems: physicochemical characterization and enhanced antibacterial activity. , 2005, Current drug delivery.

[33]  S. Doggrell.  Recent pharmacological advances in the treatment of preterm membrane rupture, labour and delivery , 2004, Expert opinion on pharmacotherapy.

[34]  D. Cabrol,et al.  Pharmacokinetics of Tocolytic Agents , 2004, Clinical pharmacokinetics.

[35]  T. Ohno,et al.  Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. , 2003, The Journal of pediatrics.

[36]  H. Won,et al.  Therapeutic effect of cyclo-oxygenase inhibitors with different isoform selectivity in lipopolysaccharide-induced preterm birth in mice. , 2003, American journal of obstetrics and gynecology.

[37]  N. Fisk,et al.  A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. , 2003, American journal of obstetrics and gynecology.

[38]  G. Dekker,et al.  Calcium channel blockers for inhibiting preterm labour. , 2003, The Cochrane database of systematic reviews.

[39]  G. Saade,et al.  The effect of in utero exposure to indomethacin on the need for surgical closure of a patent ductus arteriosus in the neonate. , 2001, American journal of obstetrics and gynecology.

[40]  C. Landen,et al.  Prostaglandin inhibitors as tocolytic agents. , 2001, Seminars in perinatology.

[41]  W. Grobman,et al.  Indomethacin Tocolysis and Intraventricular Hemorrhage , 2001, Obstetrics and gynecology.

[42]  V. Hasselblad,et al.  Management of preterm labor. , 2000, Evidence report/technology assessment.

[43]  P. Diwan,et al.  Preparation and Pharmacodynamic Evaluation of Liposomes of Indomethacin , 2000, Drug development and industrial pharmacy.

[44]  A. Jefferies,et al.  The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo‐controlled trial , 1999, British journal of obstetrics and gynaecology.

[45]  R. Bajoria,et al.  Liposomal thyroxine: a noninvasive model for transplacental fetal therapy. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  R. Bajoria,et al.  Effect of Surface Charge of Small Unilamellar Liposomes on Uptake and Transfer of Carboxyfluorescein across the Perfused Human Term Placenta , 1997, Pediatric Research.

[47]  H. Wiles,et al.  The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. , 1997, American journal of obstetrics and gynecology.

[48]  R. Bajoria,et al.  Effect of the Size of Liposomes on the Transfer and Uptake of Carboxyfluorescein by the Perfused Human Term Placenta , 1997, The Journal of pharmacy and pharmacology.

[49]  J. Štulc.  Placental transfer of inorganic ions and water. , 1997, Physiological reviews.

[50]  M. Bonati,et al.  Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion. , 1996, The Journal of pharmacology and experimental therapeutics.

[51]  W. Kox,et al.  Uptake of drug-carrier liposomes by placenta: transplacental delivery of drugs and nutrients. , 1995, The Journal of pharmacology and experimental therapeutics.

[52]  D. Lewis,et al.  Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate , 1994 .

[53]  Gloor Jm,et al.  Prenatal maternal indomethacin use resulting in prolonged neonatal renal insufficiency. , 1993 .

[54]  R. Newman,et al.  Randomized trial of intraumbilical vein oxytocin in midtrimester pregnancy losses. , 1993, American journal of obstetrics and gynecology.

[55]  H. Madhav,et al.  Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. , 1993, American journal of obstetrics and gynecology.

[56]  K. Moise,et al.  Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. , 1993, American journal of obstetrics and gynecology.

[57]  K. Moise,et al.  The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry: a randomized, double-blind study. , 1993, American journal of obstetrics and gynecology.

[58]  K. Moise,et al.  The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing and body movements: a prospective, randomized, double-blind, placebo-controlled clinical trial. , 1992, American journal of obstetrics and gynecology.

[59]  O. Ylikorkala,et al.  A Randomized Double-Dummy Comparison Between Indomethacin and Nylidrin in Threatened Preterm Labor , 1991, Obstetrics and gynecology.

[60]  T. R. Johnson,et al.  Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. , 1991, American journal of obstetrics and gynecology.

[61]  K. Moise,et al.  Long-Term Indomethacin Therapy Decreases Fetal Urine Output and Results in Oligohydramnios , 1991, American journal of perinatology.

[62]  D. Moore,et al.  Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour , 1990, British journal of obstetrics and gynaecology.

[63]  K. Moise,et al.  Placental transfer of indomethacin in the human pregnancy. , 1990, American journal of obstetrics and gynecology.

[64]  R. Knuppel,et al.  Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor; A randomized study , 1989, Obstetrics and gynecology.

[65]  H. Zahradnik,et al.  The effect of acetylsalicylic acid and indomethacin on the catecholamine- and oxytocin-induced contractility and prostaglandin (6-keto-PGF1 alpha, PGF2 alpha)-production of human pregnant myometrial strips. , 1987, Prostaglandins.

[66]  E. Shalev,et al.  Further study of the inhibition of premature labor by indomethacin. Part I , 1984, Journal of perinatal medicine.

[67]  B. E. Ryman,et al.  The fate in vivo of liposomally entrapped drugs in pregnant rats. , 1980, Biochemical Society transactions.

[68]  R. White,et al.  The inhibition of premature labor with indomethacin. , 1980, American journal of obstetrics and gynecology.